Roman Agafonov
Associate Director C4 Therapeutics Inc
Roman Agafonov is Associate Director of Biochemistry, Biophysics & Structural Biology at C4 Therapeutics, where he leads biochemistry and biophysics strategy for targeted protein degradation programs. With more than 15 years of experience in mechanistic characterisation of protein–protein and protein–small molecule interactions, Roman oversees hit identification, new target evaluation, and the integration of advanced screening and structural methods to understand degrader behaviour. He has extensive expertise in dissecting ternary complex formation, cooperativity, and kinetics to guide degrader design. At the Summit, Roman will discuss how biophysics can enhance prediction of cellular degradation outcomes and support degrader optimisation.
Seminars
This interactive, session explore the key lessons, tools, and strategies shared across the summit, and invites participants to reflect on what they will take back to their organizations. This session brings together experimentalists, computational biophysicists, and AI specialists to explore the bigger picture providing you the opportunity to have honest conversations with your industry colleagues about the biggest opportunities for biophysics to evolve across discovery, screening, and analytical development.
Key Discussion Themes:
- What did you learn that will meaningfully change your approach to biophysics, in screening, characterization, or developability?
- Which techniques, workflows, or decision-making frameworks will you apply immediately in your own programs?
- Where are the biggest gaps in current biophysical capabilities and what innovations do we want to see from vendors, academia, and internal R&D in the next 3–5 years?
- How can discovery and analytical groups collaborate more effectively to reduce friction, avoid rework, and increase translational success?
- Which complex targets or modalities remain ‘unsolved,’ and what new tools or cross-functional integrations are needed to unlock them?
Blue Sky Thinking & Audience Feedback: What does the ideal future-state biophysical toolbox look like? High-throughput? Label-free? More physiologically relevant? AI-integrated?
